Since WRN‐depleted cancer cells or WS patient‐derived cells are highly sensitive to TOP1 inhibitors, we envisaged that WRN might be orchestrating TOP1cc removal and subsequent NF‐κB activation to offer therapeutic resistance in WRN‐proficient cells. The gene discussed is TOP1; the disease is cancer.